Prevalence, predictors, and natural history of hypophosphatemia following iron infusion.

ABSTRACT: Iron deficiency is the leading cause of anemia, which affects 1 quarter of the adult population globally. Intravenous iron is a well-established treatment option and is generally well tolerated. However, there is increasing recognition that it can cause hypophosphatemia, which can result in fatigue, nausea, myalgia, weakness, and osteomalacia. We sought to determine the prevalence, natural history, and predictors of hypophosphatemia following iron infusion in a tertiary hospital. All adult patients who received 1 or more iron infusions between January 1, 2019 and December 31, 2021 were included in this retrospective study. A total of 2367 subjects were identified, receiving a total of 7063 infusions over the study period. Hypophosphatemia was defined as a serum phosphate level of <0.75 mmo

SUBMITTER: Dawson C 

PROVIDER: S-EPMC12723802 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature